Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Journal of Translational Medicine|May 28, 2011
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patientsLuca Sigalotti, Elisabetta Fratta, Ettore Bidoli, et al.Scientific Reports|January 13, 2021
A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomasValentina Lupato, Jerry Polesel, Fabio Biagio La Torre, et al.Molecular Oncology|June 3, 2021
The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanomaBarbara Montico, Giorgio Giurato, Giovanni Pecoraro, et al.Journal of Translational Medicine|June 15, 2010
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesLuca Sigalotti, Alessia Covre, Elisabetta Fratta, et al.Cancer Immunology, Immunotherapy : CII|November 10, 2012
Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotideSandra Coral, Giulia Parisi, Hugues J M G Nicolay, et al.Frontiers in Oncology|December 13, 2021
Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-AnalysisJerry Polesel, Anna Menegaldo, Giancarlo Tirelli, et al.Journal of Cellular Physiology|February 4, 2010
Epigenetically regulated clonal heritability of CTA expression profiles in human melanomaElisabetta Fratta, Luca Sigalotti, Francesca Colizzi, et al.Cancers|May 13, 2023
Rising Trend in the Prevalence of HPV-Driven Oropharyngeal Squamous Cell Carcinoma during 2000-2022 in Northeastern Italy: Implication for Using p16INK4a as a Surrogate Marker for HPV-Driven CarcinogenesisPaolo Boscolo-Rizzo, Jerry Polesel, Annarosa Del Mistro, et al.Critical Reviews in Oncology/Hematology|May 15, 2022
Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncologyElena Muraro, Rebecca Romanò, Giuseppe Fanetti, et al.Cell Death & Disease|May 24, 2020
Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapyBarbara Montico, Francesca Colizzi, Giorgio Giurato, et al.Pageof 4